Prostate cancer
Conditions
Interventions
Control group: Patients treated with regular 3-monthly based goserelin 10.8 mg
injections, regardless of testosterone level.
Study group: Patients will be treated according to the following algorith
Sponsors
Sint Franciscus Gasthuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Informed consent * Male > 18 years * Diagnosed with prostate cancer with a clinical indication for ADT (*2 years or permanently) * Patients can be included before the first injection of goserelin 10.8mg and in the first two months after the first injections of goserelin 10.8 mg.
Exclusion criteria
Exclusion criteria: * Patients receiving anti-androgens (excluding bicalutamide for 4 weeks around the first LHRH agonist) * Patients with a history of hypersensitivity to LHRH agonists * Patients not able to visit hospital*s laboratory for blood sampling
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean number of goserelin injections 10.8mg during the 24 months follow-up period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: difference in time to castrate refractory disease and difference in treatment costs between the two strategies. | — |
Countries
Netherlands
Outcome results
None listed